Karolinska University Hospital / Karolinska Universitetssjukhuset

Human resident liver myeloid cells protect against metabolic stress in obesity (2023) Barreby E, Strunz B, Nock S, Naudet L, Shen JX, Johansson H, Sönnerborg I, et al. Journal article Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study. (2023) Naveen R, Nikiphorou E, Joshi M, Sen P, Lindblom J, Agarwal V, Lilleker JB, et al. Journal article Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study (2023) Doskaliuk B, Ravichandran N, Sen P, Day J, Joshi M, Nune A, Nikiphorou E, et al. Journal article High fatigue scores in patients with idiopathic inflammatory myopathies: a multigroup comparative study from the COVAD e-survey (2023) Grignaschi S, Kim M, Zanframundo G, Ravichandran N, Lilleker JB, Sen P, Joshi M, et al. Journal article Pain in individuals with idiopathic inflammatory myopathies, other systemic autoimmune rheumatic diseases, and without rheumatic diseases: A report from the COVAD study (2023) Shinjo SK, Kim M, Hoff LS, Missé RG, Sen P, Naveen R, Day J, et al. Journal article Enzymatically dissociated muscle fibers display rapid dedifferentiation and impaired mitochondrial calcium control (2022) Gineste C, Youhanna S, Vorrink SU, Henriksson S, Hernández A, Cheng AJ, Chaillou T, et al. Journal article, Original article A genome-wide association study with tissue transcriptomics identifies genetic drivers for classic bladder exstrophy (2022) Mingardo E, Beaman G, Grote P, Nordenskjöld A, Newman W, Woolf AS, Eckstein M, et al. Journal article Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study (2022) Wong SW, Bar N, Paris L, Hofmeister CC, Hansson M, Santoro A, Mateos MV, et al. Conference contribution Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522 (2022) Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur H, Kuemmel S, Bergh J, et al. Conference contribution SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis (2022) Efe C, Tascilar K, Gerussi A, Bolis F, Lammert C, Ebik B, Stättermayer AF, et al. Journal article